Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción IMRN?
El precio actual de IMRN es de $1.89, ha increased un 4.41% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Immuron Ltd?
Immuron Ltd pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Immuron Ltd?
La capitalización bursátil actual de Immuron Ltd es $10.7M
